Universal High Throughput GPCR Screening Assay

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$476,876.00
Award Year:
2009
Program:
SBIR
Phase:
Phase I
Contract:
1R43MH085368-01A1
Award Id:
94017
Agency Tracking Number:
MH085368
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
1420 5TH AVE, SUITE 2600, SEATTLE, WA, 98101
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
033364923
Principal Investigator:
JOHN BERGMANN
(206) 623-4688
JBERGMANN@OMEROS.COM
Business Contact:
DEMOPULOS GREGORY
() -
gdemopulos@omeros.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): G-protein coupled receptors (GPCR) are a family of cell surface proteins involved in mediating many of the biological actions of neurotransmitters in the brain. It has been estimated that there are approximately 865 GPC Rs in the human genome, making them one of the largest gene families known. The brain is particularly rich in GPCRs, expressing over 90% of all known non-sensory receptors. Approximately one third of these GPCRs are termed orphan GPCRs (oGPCRs), with no kn own ligand or function. Understanding the functions of CNS oGPCRs may provide opportunities in the development of new drugs to better treat common mental disorders affecting millions of people in the US. Omeros has employed a unique two-pronged approach to discovering drugs targeting oGPCRs. First, in vivo gene knockout technology is employed to identify potential functions of these oGPCRs and enable the selection of the most interesting oGPCRs to pursue. Second, we are investigating a novel in vitro techno logy for high throughput screening of ligands including antagonists, reverse agonists, and agonists to GPCRs. There is no requirement for control agonists which makes this technology ideal for screening oGPCRs. We will validate a high throughput assay base d on this technology. This phase I SBIR will confirm that the technology can be utilized as a high through- put assay using GPCRs with known peptidergic and aminergic ligands. These receptors will be screened using both an industry standard activity based screen (FLIPR) and this novel assay. A finding that the same compounds can be identified by both assays will serve to validate this new, totally general assay technology. Such validation will allow Omeros to harness this assay to identify active ligands to a variety of exciting oGPCRs that have the potential to serve as targets for important CNS based disorders. PUBLIC HEALTH RELEVANCE: Approximately one third of the G-protein coupled receptors (GPCRs) that mediate many of the biological actions of neurotra nsmitters in the brain have no known ligand or function and are termed orphan GPCRs (oGPCRs). The goal of these studies is to validate a novel technology to discover drugs against any GPCR including oGPCRs. This validation will enable the discovery of acti ve compounds targeting this important class of molecules and could result in the development of a new generation of CNS drugs.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government